ZC4H2

Across TCGA pan-cancer cohorts, ZC4H2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZC4H2 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher ZC4H2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZC4H2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCS, UCEC, and BRCA are the cancer types where ZC4H2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.210	0.695	.001	30	view →
UCEC	DFS	Median	II,III,IV	0.922	0.437	.027	20	view →
BRCA	OS	Median	III,IV	0.027	0.907	<.001	16	view →
COAD	OS	Median	All	0.500	0.871	<.001	12	view →
LUSC	DFS	Median	All	0.373	0.804	.002	3	view →
LUAD	OS	Median	II,III,IV	0.237	0.709	.039	3	view →
SKCM	DFS	Median	III,IV	0.842	0.242	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZC4H2–UCS (OS)

Open the UCS breakdown →